[儿科霍奇金淋巴瘤的临床特征和生存分析:多中心研究]
Ying Lin1, Li-Li Pan1, Shao-Hua LE1
1Union Clinical Medicine College of Fujian Medical University, Fuzhou 350001, China.
概括
儿科霍奇金淋巴瘤 (HL) 的预后很好. 诊断时的大型瘤和化疗后缺乏完全反应表明患有这种癌症的儿童前景不佳.
科学领域:
- 儿科瘤学 儿科瘤学
- 血液学 血液学 血液学
- 临床研究 临床研究
背景情况:
- 霍奇金淋巴瘤 (HL) 是淋巴系统的癌症.
- 了解其特征和儿童的预后对于有效治疗至关重要.
研究的目的:
- 研究儿科霍奇金淋巴瘤的临床病理特征.
- 确定影响HL儿童预后结果的预后因素.
主要方法:
- 从诊断出HL的儿童 (2011-2023) 的临床数据的回顾性分析.
- 风险分层分为低 (R1),中等 (R2) 和高 (R3) 的风险组.
- ABVD和HL-2013化疗方案的比较.
- 使用考克斯回归的预测因素分析.
主要成果:
- 总体完整反应 (CR) 率为42% (2个周期) 和68% (4个周期).
- 与ABVD相比,HL-2013疗法在低风险 (R1) 组中显示出更高的CR率.
- 5年无事件生存率 (EFS) 为83%,总生存率为97%,无治疗失败率为88%.
- 大型瘤质量和4个周期后未能达到CR是较低EFS的独立风险因素.
结论:
- 儿科霍奇金淋巴瘤通常表现出有利的预后.
- 巨大的瘤负担和不完整的治疗反应是儿科HL预后较差的指标.
相关概念视频
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Comparing the Survival Analysis of Two or More Groups
299
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
299
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


